TERANTE Trademark

Trademark Overview

On Tuesday, April 19, 2022, a trademark application was filed for TERANTE with the United States Patent and Trademark Office. The USPTO has given the TERANTE trademark a serial number of 97370041. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 1, 2025. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The TERANTE trademark is filed in the Pharmaceutical Products category with the following description:

Antiretroviral drug for the treatment of HIV-1 infection in adults
terante

General Information

Serial Number97370041
Word MarkTERANTE
Filing DateTuesday, April 19, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 28, 2023

Trademark Statements

Goods and ServicesAntiretroviral drug for the treatment of HIV-1 infection in adults

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 25, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events

Event DateEvent Description
Friday, April 22, 2022NEW APPLICATION ENTERED
Monday, April 25, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 24, 2023ASSIGNED TO EXAMINER
Wednesday, January 25, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, February 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 2, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, February 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 8, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 28, 2023PUBLISHED FOR OPPOSITION
Tuesday, February 28, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 25, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 16, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 16, 2023SOU EXTENSION 1 FILED
Wednesday, August 16, 2023SOU EXTENSION 1 GRANTED
Friday, August 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 3, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, April 3, 2024SOU EXTENSION 2 FILED
Wednesday, April 3, 2024SOU EXTENSION 2 GRANTED
Thursday, April 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 26, 2024SOU TEAS EXTENSION RECEIVED
Thursday, September 26, 2024SOU EXTENSION 3 FILED
Thursday, September 26, 2024SOU EXTENSION 3 GRANTED
Thursday, September 26, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 13, 2025SOU TEAS EXTENSION RECEIVED
Thursday, March 13, 2025SOU EXTENSION 4 FILED
Friday, March 14, 2025SOU EXTENSION 4 GRANTED
Friday, March 14, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 1, 2025ABANDONMENT - NO USE STATEMENT FILED
Monday, December 1, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

terante adults infection treatment drug antiretroviral